Please do not leave this page until complete. This can take a few moments.
The 500th medical device for patients with spinal cord injuries has been placed by Marlborough manufacturer ReWalk Robotics.
According to the company, the first device was placed in 2011 to the Vatican Hospital in Rome, and the device became the first exoskeleton system to be cleared by U.S. Food and Drug Administration for U.S. sales.
“Most of all, we see this moment as a chance to reflect on the myriad lives that have been impacted by the technology,” CEO Larry Jasinski said in a press release. “Every single patient was told he or she would never walk again. Innovation and their determination has helped spinal cord injured patients stand up and regain many of the daily life functions they thought were lost forever.”
The company is now looking to increase insurance coverage for spinal cord injury patients. So far, national coverage policies are in place in Germany, Italy and with the U.S. Department of Veterans Affairs.
ReWalk said it continues to work with payers on individual system procurements and private coverage policies. That has resulted in 38 different payers in the U.S. and 39 in Germany providing positive coverage decisions for the systems.
The news comes as the company released its third-quarter financial results, in which it lost $4.5 million.
As of the end of September, the company had $5.2 million in cash compared to $14.5 million at the end of 2017.
Despite positive news on the insurance coverage front and an application for European sales clearance, the company is exploring all financing options to execute its strategy and stay afloat, Jasinksi said.
An upcoming FDA application for a device tailored to stroke patients is expected in early 2019, and a product could be on the market by next year’s third quarter.
The company took in $1.6 million in revenue for the quarter, compared to $1.7 million in the same period last year.
For the year, the company has lost $16.6 million.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments